Legal Status and Side Effects

Semaglutide is one of the most thoroughly regulated peptides in the world. Its approvals, however, cover only particular products from an approved manufacturer, with a set dose, leaflet and quality standard. This page sets out what is approved, why other material is treated differently, and what regulators say about safety.

Approved Products by Region

• European Union: the European Commission has authorised Ozempic (2018) and Rybelsus (2020) for type 2 diabetes, and Wegovy (2022) for weight management. The European Medicines Agency (EMA) monitors their safety across all member states.
• United Kingdom: the MHRA has authorised all three medicines. On the NHS, access to Wegovy for weight loss is limited by criteria set by NICE.
• United States: the FDA has approved Ozempic, Rybelsus and Wegovy. Later approvals added heart, kidney and liver indications.
• Everywhere they are approved, these are prescription medicines dispensed by pharmacies.

Why Research-Grade Semaglutide Is Not a Medicine

Under EU law, any product offered to prevent or treat a disease in people is a medicinal product and needs a marketing authorisation before it can be sold. Research-grade semaglutide is usually a freeze-dried powder in a vial with no leaflet, dose instructions or authorisation. It is not manufactured or tested under the rules that apply to licensed medicines, so its purity, strength and sterility depend on whoever made it. Rules on import and possession also differ from country to country, and readers should check their own national law.

Frequent Side Effects

In the studies, most side effects involved the digestive system and eased over time:

• Nausea, which affected many people, especially in the first weeks and after each dose increase
• Diarrhoea, vomiting, constipation and stomach pain
• Burping, bloating, heartburn and a feeling of fullness
• Tiredness and headache, and low blood sugar when used with insulin or a sulfonylurea

Warnings From Regulators

• Pancreas: acute pancreatitis has been reported. Severe, lasting stomach pain needs urgent medical review, and semaglutide should be stopped if pancreatitis is suspected.
• Gallbladder: gallstones were more common than with placebo, especially with larger weight losses.
• Diabetic eye disease: in people with existing retinopathy, a fast drop in blood sugar can make it worse for a while, so eye checks are advised.
• Optic nerve: in June 2025 the EMA's safety committee concluded that NAION, a sudden loss of blood supply to the optic nerve, is a very rare side effect of semaglutide medicines.
• Thyroid: semaglutide caused thyroid C-cell tumours in rodents. The US label carries a boxed warning and rules out use in people with a personal or family history of medullary thyroid cancer or MEN 2.
• Mood: after reviewing reports of suicidal thoughts, the EMA's safety committee said in April 2024 that the evidence did not support a causal link.
• Fluids and surgery: dehydration from vomiting or diarrhoea can harm the kidneys, and doctors should know about the drug before anaesthesia because it slows stomach emptying.

The Bottom Line

The benefits and risks of semaglutide are well documented, but only for authorised medicines prescribed and monitored by a doctor. Anyone thinking about semaglutide for their own health should start with a medical appointment. Labs handling research-grade material must follow their institution's safety rules and national law.

This summary is general information only and is not legal or medical advice.